The analgesic domain of IL-2

被引：17

作者：

Wang, Y ^{[1
]}

Li, L ^{[1
]}

Liu, JF ^{[1
]}

Wang, ZY ^{[1
]}

Jiang, CL ^{[1
]}

Liu, XY ^{[1
]}

机构：

[1] CHINESE ACAD SCI,SHANGHAI INST BIOCHEM,SHANGHAI 200031,PEOPLES R CHINA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 1997年 / 230卷 / 03期

关键词：

D O I：

10.1006/bbrc.1996.5961

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Human recombinant interleukin-2 (IL-2) has been showed to exert an analgesic effect and some experiments suggested that opioid receptors were involved. Because the aromatic residues at the N-termini of opioid peptides are crucial for their binding to the opioid receptors, all nine aromatic residues in IL-2 were mutated by site-directed mutagenesis and both the analgesic activity and the immune activity of the wild-type and mutated IL-2 were tested, The result indicated that there exists a putative analgesic function domain in IL-2, in which Phe44, Tyr45, Tyr107, and Phe117 mere essential. These four residues are located close together at the tertiary structure level of IL-2. (C) 1997 Academic Press.

引用

页码：542 / 545

页数：4

共 50 条

[41] Expression of IL-2α and IL-2β receptors on the membrane surface of human sperm [J].

Fierro, R ;

Schwed, P ;

Foliguet, B ;

Grignon, G ;

Bene, MC ;

Faure, G .

ARCHIVES OF ANDROLOGY, 2002, 48 (05) :397-404

[42] Neutralizing IL-2 antibodies enhance in vivo IL-2 activity by prolonging its half-life and reducing IL-2 binding to IL-2 receptor-expressing cells [J].

Bouchaud, G. ;

Krieg, C. ;

Boyman, O. .

ALLERGOLOGIE, 2011, 34 (02) :100-100

[43] CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production [J].

Matzkies, F ;

Manger, B ;

Kalden, JR ;

Nagel, T .

FASEB JOURNAL, 1999, 13 (04) :A628-A628

[44] Treatment of old mice with IL-2 corrects dysregulated IL-2 and IL-4 production [J].

Kirman, I ;

Zhao, KS ;

Tschepen, I ;

Szabo, P ;

Richter, G ;

Nguyen, H ;

Weksler, ME .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (07) :1009-1015

[45] ROLE OF INTERLEUKIN-2 (IL-2) IN CANCER-RELATED IMMUNE-DEFICIENCY - INVITRO RESPONSE TO IL-2, PRODUCTION OF IL-2, AND IL-2 RECEPTOR EXPRESSION IN PATIENTS WITH ADVANCED CANCER [J].

MANTOVANI, G ;

COIANA, A ;

MASSIDDA, A ;

PROTO, E ;

FLORIS, C ;

MACCIO, A ;

PUSCEDDU, G ;

DELGIACCO, GS .

CANCER DETECTION AND PREVENTION, 1988, 12 (1-6) :149-159

[46] IL-2 and its spliced variant IL-2 delta2 and il-2 delta3 in the pathogenesis of B-CLL. [J].

Kaminski, A ;

Demaine, A ;

Prentice, AG .

BLOOD, 1999, 94 (10) :300B-300B

[47] TRANSCRIPTION AND TRANSLATION DEPENDENT INDUCTION OF INTERLEUKIN-2 (IL-2) AND IL-2 RECEPTORS [J].

WANG, Y ;

WALKER, C ;

STADLER, BM ;

DEWECK, AL .

IMMUNOLOGY LETTERS, 1984, 8 (04) :227-231

[48] The soluble IL-2 receptor α/CD25 as a modulator of IL-2 function [J].

Lokau, Juliane ;

Petasch, Lynn M. ;

Garbers, Christoph .

IMMUNOLOGY, 2024, 171 (03) :377-387

[49] Both integrated and differential regulation of components of the IL-2/IL-2 receptor system [J].

Kim, Hyoung Pyo ;

Imbert, Jean ;

Leonard, Warren J. .

CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (05) :349-366

[50] Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2 [J].

T. J. P. Spoormakers ;

W. R. Klein ;

J. J. L. Jacobs ;

Th. S. G. A. M. Van Den Ingh ;

J. W. Koten ;

W. Den Otter .

Cancer Immunology, Immunotherapy, 2003, 52 :179-184

← 1 2 3 4 5 →